An economic viewpoint on alternative strategies for identifying persons with hereditary nonpolyposis colorectal cancer.
other · Level V
Where this comes from
- Record sourced from PubMed, PMID 14501830.
- Also identified by PMC identifier 2692576.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
There is uncertainty regarding the optimal strategy for identifying mutation carriers among those with hereditary nonpolyposis colorectal cancer (HNPCC). We used decision analysis to compare the cost-effectiveness of 4 strategies among those with newly diagnosed colon cancer: (1) clinical and family history followed by microsatellite instability testing and germline testing (Bethesda guidelines); (2) universal microsatellite instability testing; (3) germline testing of those who meet clinical and family history criteria; and (4) universal germline testing. The added cost per year of life saved (YLS) for each strategy was as follows: (1) 11,865 US dollars/YLS, (2) 35,617 US dollars/YLS, (3) 49,702 US dollars/YLS, and (4) 267,548 US dollars/YLS. The Bethesda guidelines are the most cost-effectiveness approach to screen persons for HNPCC.
Medical subject headings
- Colorectal Neoplasms, Hereditary Nonpolyposis
- Genetic Testing